scan code for digital copy and hyperlinked sources

CHARITY WATCHLIST

American Parkinson Disease Association



EMBRYONIC STEM CELL RESEARCH

While this <u>2018 article</u> explains what human embryonic stem cells are, the
American Parkinson's Disease Association doesn't specifically say if it does
or does not fund the utilization of human embryonic stem cells in therapy for
Parkinson's. However, it is implied that APDA does not condemn the use of
human embryonic stem cells by its vague answer:

"Does APDA fund any stem cell research? APDA is committed to funding research to further our understanding of PD and to bring new treatments to patients as quickly as possible."

 In a Fall 2007 newsletter, Jessica Hahn, coordinator of the American Parkinson Disease Assocation's Information and Referral Center, wrote an article on the "benefits" of using human embryonic stem cells, despite the controversy of utilizing them. She writes:

"Using embryonic stem cells to replace dopamine neurons lost in people with Parkinson's disease may be possible someday, but not in the very near future. Attempts to treat humans with fetal cells (which are like embryonic stem cells) have been unsuccessful. It would be very unfortunate if people delayed having other types of therapy expecting to have stem cell treatments. We can, however, see embryonic stem cells being used in the future as a means of delivering other kinds of biological substances such as nerve growth factor, to the brain." (p. 3)

 In an email reply to American Life League on 9/5/2023, the American Parkinson Disease Association confirmed its support for research utilizing human embryonic stem cells: American Parkinson Disease Association apdaparkinson.org

Tax ID: 13-1962771

PO Box 61420 Staten Island, NY 10306

phone: 800.223.2732

Mission

Provide support, education, and research to help everyone impacted by Parkinson's disease live life to the fullest.

Focus

neurology, neuroscience, brain and nervous system disorders

"APDA does not currently support research that utilizes human embryonic stem cells, although this would not be a limitation for us if a potential researcher applies for funding in the future."

-Rebecca Gilbert, MD, PhD|Senior Vice President, Chief Scientific Officer

